Nold R, Frank M, Kajdan U, Trost U, Klose K J, Arnold R
Abteilung Gastroenterologie und Stoffwechsel, Philipps-Universität, Marburg.
Z Gastroenterol. 1994 Apr;32(4):193-7.
14 patients with metastatic endocrine gastro-entero-pancreatic carcinoma (6 patients with Carcinoid-syndrome, 3 with gastrinoma and 5 with non-functioning tumor) have been treated with Octreotide 3 x 200 micrograms/die plus Interferon-Alpha 3 x 5 Mio U/week after documented tumor progression during preceding Octreotide-monotherapy. 6 out of 14 patients responded favourable to the treatment: one patient with partial regression and 5 patients with stillstand of tumor growth. In only one patient initial tumor stillstand for 6 months was followed by tumor progression whereas in five patients a beneficial effect on tumor growth could be documented up to 34 months. Inhibition of tumor growth and tumor progression was not necessarily paralleled by respective changes in peripheral hormone levels. These results should initiate a controlled prospective study to prove the hypothesis that in patients with metastasized endocrine gastro-entero-pancreatic tumors the combination of Octreotide and Interferon-Alpha is superior to monotherapy with Octreotide or Interferon-Alpha and to identify those patients who respond to this combined therapy.
14例转移性内分泌胃肠胰癌患者（6例类癌综合征患者、3例胃泌素瘤患者和5例无功能性肿瘤患者），在先前奥曲肽单药治疗记录显示肿瘤进展后，接受奥曲肽3×200微克/日加α干扰素3×500万单位/周的治疗。14例患者中有6例对治疗反应良好：1例部分缓解，5例肿瘤生长停滞。仅1例患者最初肿瘤停滞6个月后出现肿瘤进展，而5例患者对肿瘤生长的有益作用可持续34个月。肿瘤生长和进展的抑制并不一定与外周激素水平的相应变化平行。这些结果应启动一项对照前瞻性研究，以证实以下假设：在内分泌胃肠胰转移瘤患者中，奥曲肽和α干扰素联合治疗优于奥曲肽或α干扰素单药治疗，并确定那些对这种联合治疗有反应的患者。
